Featured Research

from universities, journals, and other organizations

A new postal code for cancer: Targeting nano-containers to starve, kill cancer cells

Date:
February 11, 2014
Source:
Albert-Ludwigs-Universität Freiburg
Summary:
Scientists have discovered that a polymer can provide a key to get into tumors. Researchers have developed a new paradigm to home nanoparticles, containers that measure a few 100 nanometers in size, to endothelial cells.

Immunofluorescence image shows nanoparticles targeted to endothelial cells. The red particles turn orange when overlapping with the green caveolin in the lipid rafts of the cells.
Credit: Julia Voigt / Prasad Shastri

Scientists have discovered that a polymer can provide a key to get into tumors: Prof. Prasad Shastri, Director of the Institute of Macromolecular Chemistry and core member of the cluster of excellence BIOSS Centre for Biological Signalling Studies at the University of Freiburg, and graduate students Julia Voigt and Jon Christensen have developed a new paradigm to home nanoparticles, containers that measure a few 100 nanometers in size, to endothelial cells.

Using just charged polymers with the right affinity for cell lipids the team has developed nanoparticles that can recognize specific cell types simply by their chemical properties. "This is a remarkable discovery, as it allows for the first time to target a specific cell type purely through biophysical principles, and without using the traditional ligand-receptor approach" says Prof. Shastri who led the study. Until now researchers placed molecules on nanoparticles that can latch onto proteins on cell surface -- called receptors.

These receptors act as an address or a biological postal code. However in tumors these addresses can change rapidly with time. To solve this lack of precision Shastri and team developed particles that are delivered to endothelial cells using a biophysical approach. "This delivery approach does not require a biological postal code for targeting of nanoparticles and is an important step forward in developing nanoparticle based systems for treating cancers" says Julia Voigt the lead author of the paper.

Cancers are very hungry tissues and they need constant nourishment. This is provided through their own supply of blood vessels. "By going after endothelial cells that make up these blood vessels, we can starve the tumor or kill it with one payload" says Jon Christensen who is a co-author on this study and works on tumor metastasis.

Nanoparticles are used to deliver therapeutics in treating cancers. These very small pills, cornerstones of nanomedicine, get injected into the body and reach the tumor cells via the bloodstream. When they find the targeted cells, they need to be eaten so that the drug can act within the cell. This mechanism is called receptor-mediated endocytosis. Shastri and his team looked to develop a new approach that targets a transport process that is dominant in endothelial cells. It turns out that a structure called caveolae is found in large amounts on endothelial cells. Caveolae are "lipid rafts" on the cell membrane and are one of the doors into the endothelial cells. Prof. Shastri and his team discovered that by decorating nano-pills made of lipids with negatively charged polymers, nanoparticles can preferentially enter through this door. "How exactly these charged polymers enable the nanoparticles to unlock this door we are not sure yet, but we feel confident that with further studies this method could usher in a new approach to delivery of drugs in general" says Shastri. This project was funded by Nano@matrix supported by INTERREG and the cluster of excellence BIOSS Centre for Biological Signalling Studies.


Story Source:

The above story is based on materials provided by Albert-Ludwigs-Universität Freiburg. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. Voigt, J. Christensen, V. P. Shastri. Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae. Proceedings of the National Academy of Sciences, 2014; DOI: 10.1073/pnas.1322356111

Cite This Page:

Albert-Ludwigs-Universität Freiburg. "A new postal code for cancer: Targeting nano-containers to starve, kill cancer cells." ScienceDaily. ScienceDaily, 11 February 2014. <www.sciencedaily.com/releases/2014/02/140211083814.htm>.
Albert-Ludwigs-Universität Freiburg. (2014, February 11). A new postal code for cancer: Targeting nano-containers to starve, kill cancer cells. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/02/140211083814.htm
Albert-Ludwigs-Universität Freiburg. "A new postal code for cancer: Targeting nano-containers to starve, kill cancer cells." ScienceDaily. www.sciencedaily.com/releases/2014/02/140211083814.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins